Published in
2022
March 2022, Volume 9, Issue 2, Pages 173-180; doi: 10.1097/UPJ.0000000000000291
IsoPSA Reduces Provider Recommendations for Biopsy and Magnetic Resonance Imaging in Men with Total Prostate Specific Antigen ≥4 ng/mL: A Real-World Observational Clinical Utility Study Jason M. Scovell, Daniel Hettel, Robert Abouassaly, Nima Almassi, Ryan Berglund, Todd Breaux, Christopher Weight, Wahib Isac, Anna Zampini, Elizabeth Stark, Robert Rochelle, Aimee Kestranek, Mark Stovsky, and Eric A. Klein
Objective Methodology
To assess the impact of the IsoPSA test for prostate cancer risk assessment on provider patient management decisions in a real-world clinical setting. Enrolled 900 men being evaluated for prostate cancer; 734 met inclusion criteria (age >50 years, total serum prostate specific antigen (PSA) ≥4 and <100 ng/mL and no history of prostate cancer). Compared biopsy and MRI recommendations prior to and after receiving IsoPSA results. Primary outcome: Number of biopsy and MRI recommendation changes occurring after IsoPSA testing.
Results
IsoPSA results were used to affirm or modify provider recommendations for prostate biopsy and/or MRI. • 60% change in recommendations for biopsy
- 90% of patients initially recommended for biopsy were not recommended for biopsy after clinicians received IsoPSA results ≤ 6
- 43% of patients initially NOT recommended for biopsy were recommended for biopsy after clinicians received IsoPSA results > 6
• 55% reduction in recommendations for prostate biopsy overall
Conclusion
In a real-world clinical setting, providers readily adopted IsoPSA with substantial reductions in the rate of recommended prostate biopsies and MRIs in patients with elevated PSA values (≥4 ng/mL). There was a high concordance between recommendation for or against prostate biopsy and the IsoPSA result. IsoPSA could help avoid biopsy-related discomfort and complications and reduce overdetection of indolent disease.
TRIAGE PATIENTS MORE EFFECTIVELY AND EFFICIENTLY CONSISTENT PERFORMANCE FOR BIOPSY NAÏVE AND REPEAT BIOPSY
Changes in recommendations for biopsy were identical for patients whether they had a previous negative biopsy or were biopsy naïve.
Summary of biopsies recommended before and after IsoPSA results by patient biopsy history No. Biopsies No. Biopsies % Reduction Recommended Recommended in Biopsies before IsoPSA after IsoPSA Recommended
Cohort
No.
All Subjects
734
638
284
55.5
Biopsy naïve
408
370
173
53.2
Prior neg biopsy
326
268
113
57.8
EFFICIENT PRACTICE MANAGEMENT Incorporating IsoPSA test into practice management efficiently triages elevated PSA patients into biopsy, MRI, or monitoring. IsoPSA has been incorporated into practice workflows before and after MRI demonstrating the clinical utility. ive
at
tPSA > 4
IsoPSA
g Ne
Po sit ive
Monitoring ive at
g
MRI
Ne
Po sit ive
TRUS Guided Biopsy
MR-US Fusion Biopsy
View this and other IsoPSA publications
Learn more about IsoPSA at IsoPSA.com 3615 Superior Ave. Suite 4407C ©2023 Cleveland Diagnostics, IsoPSA and all associated logos are trademarks of Cleveland Diagnostics, Inc. MKTG-VSA005
Cleveland, OH 44114